Company Overview and News

12
The Zacks Analyst Blog Highlights: AstraZeneca, salesforce, Mastercard, Lam Research and Koninklijke

8h zacks
Chicago, IL –October 19, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca (AZN - Free Report) , salesforce.com (CRM - Free Report) , Mastercard (MA - Free Report) , Lam Research (LRCX - Free Report) and Koninklijke Philips (PHG - Free Report) .
LRCX KBH BLT AZN BHPBF MA CRM CHTR AZN BHP BBL BHP BHPLF KIM

5
Top Analyst Reports for AstraZeneca, Salesforce & Mastercard

17h zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including AstraZeneca (AZN), salesforce.com (CRM) and Mastercard (MA). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
LRCX LMT CHTR TSNU AZN AZN AMAT MA TSN LAD CRM

 
Myopia And Lam Research

22h seekingalpha
Whenever shares of Lam Research have been this inexpensive in the past, they have subsequently rallied nicely.
LRCX AMAT

19
73 Technology 'Safer' Dividend WallStars For October

2018-10-17 seekingalpha
WallStars all show positive broker target price upsides. Top "safer" dividend Technology WallStar, Western Digital, showed a 74.88% gain. Top-ten averaged 50.24% per Broker estimates plus dividends. 7/10 leaders were oversold.
WSO LRCX WSO.B CY KLIC WDC STX TEL MCHP KLAC AMAT GRMN DTST UMC QCOM MXIM

3
The Disconnect Between Memory Chip Output And Processing Equipment Sales: Part 2, Equipment

2018-10-17 seekingalpha
DRAM capex spend pushouts by Samsung Electronics were largely to blame for a QoQ revenue drop by Lam Research in the recent September quarter.
LRCX SSNLF HXSCF MU AMAT BC94 SMSN HXSCL SMSD

1
Lam Research (LRCX) Beats on Q1 Earnings, Q2 Outlook Positive

2018-10-17 zacks
Lam Research Corporation (LRCX - Free Report) reported first-quarter fiscal 2019 non-GAAP earnings of $3.36 per share, which beat the Zacks Consensus Estimate by 15 cents. However, the figure decreased 36.7% sequentially. Adjusted revenues of $2.33 billion comfortably surpassed the Zacks Consensus Estimate of $2.30 billion and were slightly above the mid-point of the company’s guidance. However, the figure decreased 25.
LRCX AEIS ASML AVGO

 
The Ratings Game: Lam Research, ASML earnings spark ‘relief rally’ for chip-equipment sector, but doubts remain

2018-10-17 marketwatch
Analysts remain worried about trade-war issues for contentious sector even as stocks like Applied Materials and KLA-Tencor rise
LRCX ASML AMAT

24
50 Top Technology Dividend WallStars By Yield And Gains For October

2018-10-17 seekingalpha
WallStars all show positive broker target price upsides. Top WallStar Technology ten by net gains, STX, XRX, KLAC, CY, LRCX, RELL, CAMT, WDC, TIVO and XPER, averaged 61.15%, calculated 10/15/18.
LRCX CY XPER RELLB WDC STX KLAC XRX CAMT LYTS UMC NOK RELL TESS TIVO

49
10 Bargain-Bin Stocks to Buy

2018-10-17 investorplace - 1
The last several days have been tough ones for the market, and today aside, people haven’t been keen on stocks to buy. The S&P 500 is down more than 6% from its early October high, and appears to be testing the waters of even lower lows. For some big names like Advanced Micro Devices (NASDAQ:AMD) and FedEx (NYSE:FDX), it has been an even more harrowing phase. AMD shares are off 15% and FedEx has lost 12% for the month.
LRCX IGT AMD COF-D COF-C COF-F CELG DIS CBS FOX JELD COF-P CMCSA OC FDX COF SYF CMI X FOXA

38
The Key Question Facing Nvidia Stock

2018-10-17 investorplace - 1
It’s important not to overreact to the recent declines in Nvidia (NASDAQ:NVDA) stock. Long-term, I still believe Nvidia stock is a buy. Short-term, it has been a different story. Nvidia stock has fallen 18% in just the last eight trading sessions before today.
LRCX SOXX SQ SHOP TXN MU AMAT AMD NVDA QCOM INTC

 
Lam Research Offers Positive Surprise

2018-10-17 247wallst
When Lam Research Corp. (NASDAQ: LRCX) reported its fiscal first-quarter financial results after the markets closed on Tuesday, the company said that it had $3.36 in earnings per share (EPS) and $2.33 billion in revenue. The consensus estimates had called for $3.21 in EPS and revenue of $2.3 billion, and it the same period of last year the chip equipment maker posted EPS of $3.46 on $2.48 billion in revenue.
LRCX

2
Stock futures cool after strong rally; Fed minutes awaited

2018-10-17 channelnewsasia
U.S. stock futures fell on Wednesday, a day after Wall Street's strongest rally in seven months, as investors were disappointed with IBM's results and remained cautious ahead of the minutes of Federal Reserve's latest meeting.
LRCX ASML DAL

5
LRCX / Lam Research Corp. 8-K (Current Report)

2018-10-16 sec.gov - 5
Document FORM 8-K
LRCX

 
See The Lam Through The Trees

2018-10-16 seekingalpha
Lam Research's share price is down following China trade wars and Q418 results. Results comfortably exceeded analyst expectations but they provided weak 1Q19 guidance.
LRCX HXSCF AMAT MKSI HXSCL

 
Why Lam Research (LRCX) Could Beat Earnings Estimates Again

2018-10-15 zacks
Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Lam Research (LRCX - Free Report) , which belongs to the Zacks Semiconductor Equipment - Wafer Fabrication industry, could be a great candidate to consider.
LRCX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to LRCX / Lam Research Corp. on message board site Silicon Investor.

Lam Research: Can The Stock Price Run Sustain? Lam Research: Can The Stock Price Run Sustain? Lam Research: Can The Stock Price Run Sustain? Lam Research (LRCX, NASDAQ): To the Insiders Lam Research (LRCX, NASDAQ): To the Insiders Lam Research (LRCX, NASDAQ): To the Insiders
Semi-Equips - Buy when BLOOD is running in the streets! Semi-Equips - Buy when BLOOD is running in the streets! Semi-Equips - Buy when BLOOD is running in the streets! SYMC, LRCX, INDYY, AMCC, IH, BRAD, Articles SYMC, LRCX, INDYY, AMCC, IH, BRAD, Articles SYMC, LRCX, INDYY, AMCC, IH, BRAD, Articles
LRCX this one looks good LRCX this one looks good LRCX this one looks good
CUSIP: 512807108